Skip to main content
. 2021 Apr 8;24(4):1048–1054. doi: 10.1038/s41391-021-00343-2

Fig. 3. The cumulative incidence rates and reason of discontinuation of patients included in the PRIAS study with upfront (i.e. Group C).

Fig. 3

TBx targeted biopsies, GG Grade Group, SBx systematic biopsies.